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Abstract: It is known that bacteria showing a multi-drug resistance phenotype use several mechanisms to overcome the 
action of antibiotics. As a result, this phenotype can be a result of several mechanisms or a combination of thereof. The 
main mechanisms of antibiotic resistance are: mutations in target genes (such as DNA gyrase and topoisomerase IV); 
over-expression of efflux pumps; changes in the cell envelope; down regulation of membrane porins, and modified 
lipopolysaccharide component of the outer cell membrane (in the case of Gram-negative bacteria). In addition, adaptation 
to the environment, such as quorum sensing and biofilm formation can also contribute to bacterial persistence. Due to the 
rapid emergence and spread of bacterial isolates showing resistance to several classes of antibiotics, methods that can rap-
idly and efficiently identify isolates whose resistance is due to active efflux have been developed. However, there is still a 
need for faster and more accurate methodologies. Conventional methods that evaluate bacterial efflux pump activity in 
liquid systems are available. However, these methods usually use common efflux pump substrates, such as ethidium bro-
mide or radioactive antibiotics and therefore, require specialized instrumentation, which is not available in all laboratories.  
In this review, we will report the results obtained with the Ethidium Bromide-agar Cartwheel method. This is an easy, in-
strument-free, agar based method that has been modified to afford the simultaneous evaluation of as many as twelve bac-
terial strains. Due to its simplicity it can be applied to large collections of bacteria to rapidly screen for multi-drug resis-
tant isolates that show an over-expression of their efflux systems. The principle of the method is simple and relies on the 
ability of the bacteria to expel a fluorescent molecule that is substrate for most efflux pumps, ethidium bromide. In this 
approach, the higher the concentration of ethidium bromide required to produce fluorescence of the bacterial mass, the 
greater the efflux capacity of the bacterial cells. We have tested and applied this method to a large number of Gram-
positive and Gram-negative bacteria to detect efflux activity among these multi-drug resistant isolates. The presumptive 
efflux activity detected by the Ethidium Bromide-agar Cartwheel method was subsequently confirmed by the determina-
tion of the minimum inhibitory concentration for several antibiotics in the presence and absence of known efflux pump 
inhibitors. 
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EXISTING METHODS TO ASSESS BACTERIAL EF-
FLUX ACTIVITY  
 The increasing multi-drug resistance reported in bacterial 
clinical isolates has become a major concern in the public  
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health area given that the lack of treatment options for these 
infections, with the existing antibiotics, is becoming more 
and more problematic [1-3]. As multi-drug resistance can be 
the result of an over-expression of the bacterial efflux pump 
systems, used to extrude unrelated antibiotics prior to their 
reaching the intended targets [3], there is a need to develop 
and implement new and improved methods for a real-time 
and quick identification of efflux mediated multi-drug resis-
tant (MDR) phenotypes [4, 5]. Primarily, assessment of ef-
flux activity has been conducted using a common substrate 
of efflux pumps, such as ethidium bromide (EtBr). This 
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compound is widely used to “monitor” efflux in a given bac-
teria and its increased retention after an uncoupler of the 
proton motive force or other efflux inhibitor has been added 
[4-6]. The baseline fluorescence or the increase of EtBr that 
is retained by the bacteria prior to and after the addition of 
the uncoupler (or other type of inhibitor), is usually deter-
mined using specialized and expensive fluorometric instru-
mentation that may not be available in a clinical bacteriology 
laboratory [5, 7]. The principle of these fluorometric assays 
is the passage of EtBr across the cytoplasmic membrane and 
its subsequent intracellular accumulation inside the bacterial 
cell [8]. EtBr traverses the bacterial cell wall (in the case of 
Gram-negative bacteria via porin channels) and once inside, 
it can be concentrated to a point where it fluoresces when 
excited by ultraviolet (U.V.) light. Efflux pumps of MDR 
bacteria recognize this substrate and are able to extrude it to 
the medium [6, 8]. These efflux systems are temperature 
dependent [9] and this process will continue if the concentra-
tion of EtBr in the culture medium does not overcome the 
capacity of the bacterial efflux pump itself. Therefore, load-
ing of the bacteria with EtBr has to take place at a concentra-
tion that is well below its minimum inhibitory concentration 
(MIC) [4, 5]. This way, the signal that is generated can be 
continuously recorded under specific conditions, such as 
time, temperature and different properties of the medium (for 
example: pH; calcium availability; etc.) [5, 6]. Efflux of EtBr 
can be readily shown by the use of standard fluorometers or 
cytometers [7, 10, 11]. However, when efflux is due to over-
expressed efflux pumps, it cannot be easily shown/assessed 
by some of the conventional methods previously referred to 
[5, 12]. The current fluorometric systems used to access ef-
flux activity are in general non-physiological; usually the 
control of the temperature is restricted; the methods are 
cumbersome and do not yield data that can be subjected to 
standardization for intra-laboratory comparison. Moreover, 
due to the wide variety of instrumentation, reagents, media, 
etc., used by the many laboratories working in this area, it is 
difficult to compare and standardize the results obtained 
from these studies [4, 5]. In the recent years there have been 
several methods published that can assess efflux in a more 
dynamic and physiological way making use of fluorescent 
probes, such as EtBr, Hoechst-33342 (bisbenzimide) or 
fluorogenic compounds (for example: Fluorescein-di-β-D-
galactopyranoside) or using lipophilic dyes, such as Nile Red 
[4, 5, 6, 12-15]. The majority of these methods use a liquid 
system and need equipment that may or may not be available 
in all the clinical laboratories. Therefore, there is still an ob-
vious need to establish new and optimized assays for the 
assessment of efflux pumps of distinct bacteria, in particular 
those of clinical origin showing an MDR phenotype. Addi-
tionally, there is still a lack of methods that make use of a 
solid system and simple equipments. A new assay should be 
simple, quick to perform, reproducible and should excuse 
any specialized instrumentation for its conductance [16]. In 
MDR bacteria, the assessment of efflux pump activity can 
help to characterize the basis by which novel/existing com-
pounds inhibit efflux activity, consequently rendering the 
organism susceptible to one or several of the antibiotics to 
which it was initially resistant [8, 17-19]. If those com-
pounds were available for clinical therapy, it would be ex-
pected that the assay would have extensive implementation 
within the hospital/clinic and provide much of the guidance 
needed for the administration of the compounds to patients 
infected with an MDR bacteria [19]. Moreover, the availabil-
ity of such compounds brings benefits to the therapeutic 
regimens, resulting in the opportunity to use outdated, inex-
pensive and safe antibiotics that had been made redundant as 
a consequence of the emergence of MDR bacteria [20]. To 
describe and characterize in detail the activity of an efflux 
inhibitor, the method by which that activity is defined and 
quantified must be reliable and feasible to apply to a large 
number of inocula, yielding inter-laboratory standardization.  
ETHIDIUM BROMIDE (ETBR)-AGAR CARTWHEEL 
METHOD 
 This simple, instrument-free, agar-based method utilizes 
EtBr for the demonstration of efflux pump activity in bacte-
ria [21]. It is an improved and optimized version of the pre-
viously described EtBr-agar method [16]. This new opti-
mized method can be applied simultaneously to up to twelve 
bacterial strains to identify clinical isolates that have an over-
expressed efflux activity [21]. Each plate should include at 
least one reference strain that will serve as a comparative 
control for fluorescence analysis. However, the number of 
reference strains can be increased to two or more, depending 
on a given experiment. In addition, it allows the evaluation 
of agents that may inhibit this same activity. The effect of 
temperature on the efflux pump system can also be as-
sessed/confirmed. The methodology used is straight-forward 
employing the preparation of two sets of Trypticase Soy 
Agar (TSA) plates containing EtBr concentrations ranging 
from 0.0 to 2.5 mg/L (these concentrations may vary accord-
ing to the bacterial strain in study). The TSA plates should 
be prepared fresh on the previous or same day of the experi-
ment and kept protected from light. Overnight cultures of the 
bacterial isolates to be tested are prepared in liquid media 
and in the following day their concentration adjusted to 0.5 
of a McFarland standard. The TSA plates are then divided 
into as many as twelve sectors by radial lines, forming a 
cartwheel pattern (Fig. 1). The adjusted bacterial cultures are 
then swabbed on the EtBr-TSA plates starting from the cen-
ter of the plate to the margin. The TSA plates are then incu-
bated at 37ºC for 16 hours. After this period, the TSA plates 
are examined under a gel-imaging system (or a U.V. transil-
luminator); the minimum concentration of EtBr that pro-
duces fluorescence of the bacterial mass recorded; and the 
TSA plates photographed (Fig. 1). 
 In the case that one wants to check for the temperature 
effect, then an additional incubation step should be per-
formed. In this case, one of the TSA plate sets should be re-
incubated at 37ºC, whereas the duplicate set is transferred to 
4ºC. At the end of an additional 24 hours period, the TSA 
plates are observed and photographed again and the minimal 
concentration of EtBr that produced fluorescence at each 
temperature will be compared to that evident after the first 
incubation (at 37ºC).  
TESTING OF THE METHOD IN CLINICALLY 
RELEVANT MDR GRAM-NEGATIVE BACTERIA 
 All the clinical isolates evaluated by the EtBr-agar cart-
wheel method and inserted in this study have a confirmed 
MDR phenotype. This MDR was defined as resistance to 
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Fig. (1). Flowchart followed to test bacterial strains using the EtBr-agar Cartwheel method. MDR strains were swabbed in TSA plates con-
taining different concentrations of EtBr and incubated for 16 hours at 37ºC. Controls and clinical isolates were swabbed on EtBr-containing 
TSA plates, according to the diagram. Each EtBr-TSA plate can accommodate as many as twelve bacterial strains. The distribution of the 
strains in the TSA plate can be altered according to the desired experiment. After this, fluorescence was recorded and strains that showed 
lower fluorescence than the control (indicative of efflux activity) were selected. The efflux activity was further confirmed by determining the 
MIC of antibiotics in the presence of efflux inhibitors. Two control strains can be inserted in this study. For example, Control 1 should pre-
sent the highest fluorescence (evidence of no efflux activity or physiological activity) and Control 2 should be a strain showing no fluores-
cence or very low levels of fluorescence (indicative of an active over-expressed efflux system). These strains should be previously well char-
acterized for their efflux systems.  
three or more different classes of antibiotics [22]. Identifica-
tion and antibiotic susceptibility profile of the isolates was 
done using the VITEK2 system and provided by the micro-
biology laboratories of the collaborating hospitals (bio 
Mérieux, Marcy l´Etoile, France). The antibiotic susceptibil-
ity data was also confirmed in our laboratory by the Kirby-
Bauer method, following the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines (CLSI, 2006). Results were 
evaluated according to the CLSI breakpoints. 
 In a first approach it is necessary to establish the condi-
tions in which the assays should be performed. Therefore, 
minimum fluorescence values shown by the bacterial isolates 
should be determined. We have tested a collection of clinical 
isolates including, Gram-positive and Gram-negative strains. 
Reference strains were used in each of the assays for com-
parison terms and to help determine the fluorescence base-
line of each isolate. Clinical isolates from Gram-negative 
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bacteria included: Escherichia coli, Acinetobacter bauman-
nii, Acinetobacter genomic species 3, Enterobacter aero-
genes and Salmonella enterica serovars Enteritidis and Ty-
phimurium.  
 Escherichia coli K12 and Escherichia coli AG100TET 
strains were used as controls due to the previous well charac-
terised expression of their efflux pumps system. Escherichia 
coli K12 AG100 wild-type strain (argE3 thi-l rpsL xyl mtl 
∆(gal-uvrB) supE44), contains a fully functional AcrAB-
TolC efflux pump system. E. coli AG100TET, is a AG100 
progeny strain that was induced to high levels of resistance 
to tetracycline (TET) (MICTET of 12 mg/L) and over-
expresses acrAB [23]. E. coli K-12 AG100 has been previ-
ously characterized and was kindly offered by Hiroshi Ni-
kaido, University of California, Berkeley, California, USA 
[4, 24]. When tested by the Ethidium bromide (EtBr)-agar 
method E. coli AG100 (wild-type) shows fluorescence at a 
concentration of 0.5 mg/L of EtBr while its isogenic E. coli 
AG100TET (induced to high level resistance to TET and ex-
pressing the AcrAB efflux pump 6-fold higher than that of 
its parent [16, 21]) does not fluoresce with a concentration of 
EtBr as high as 2.5 mg/L (data not shown). In the case of the 
MDR E. coli clinical isolates, two of the ten isolates show 
less fluorescence than the remaining ones at the concentra-
tion of 2.5 mg/L of EtBr (Fig. 2).  
 A. baumannii ATCC19606 and Acinetobacter genomic 
species 3 RUH1163 were used as reference strains. As visi-
ble in Fig. (2), the two Acinetobacter strains resistant to car-
bapenem (namely meropenem (MER) and imipenem (IMI)), 
ACI6 and ACI7 don’t show fluorescence at the maximum 
concentration of EtBr tested (2 mg/L). 
 The method was also applied to Enterobacter aerogenes 
MDR clinical strains. Enterobacter aerogenes ATCC15038 
was used as a reference. Enterobacter aerogenes HMEA11 
 
Fig. (2). The EtBr-agar cartwheel method applied to Gram-negative bacteria. 
TET – Tetracycline; CIP – Ciprofloxacin. For the E. coli and Acinetobacter strains, the TSA plates shown contain 2 mg/L of EtBr while for 
Enterobacter aerogenes and Salmonella the agar plates contain 1.5 mg/L and 2.5 mg/L of EtBr, respectively. adata previously published in 
[21]. 
Escherichia colia Acinetobacter  
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shows no fluorescence at 1.5 mg/L EtBr while the ATCC 
and the other Enterobacter aerogenes strains show fluores-
cence at this same concentration (Fig. 2). 
 In the case of the Salmonella strains, Salmonella Typhi-
murium NCTC12416 and Salmonella Enteritidis 
NCTC13349 were used as reference strains since these are 
fully characterized strains. Salmonella Enteritidis 104 and 
5408 and their respective progeny 104CIP, 1ACIP, and 5408CIP 
that were induced to high level resistance to ciprofloxacin 
(CIP) by serial passage in media containing increasing con-
centrations of the antibiotic [25] were also inserted in the 
study. In the case of the Salmonella Enteritidis, the CIP in-
duced strains 5408CIP and 104CIP do not fluoresce at the high-
est concentration of EtBr used in the assay (2.5 mg/L EtBr) 
(Fig. 2). These strains have been shown to over-express their 
AcrAB efflux pump 6-fold over that of their CIP susceptible 
isogenic parental strains [26].  
APPLICATION OF THE METHOD TO CLINICAL 
RELEVANT MDR GRAM-POSITIVE BACTERIA 
 The EtBr-agar cartwheel method was also applied to 
Gram-positive pathogens causing infections in the clinical 
setting, namely, Staphylococcus aureus, Enterococcus fae-
cium and Enterococcus faecalis. S. aureus ATCC25923EtBr 
(MIC for EtBr of 200 mg/L) is a progeny strain derived from 
S. aureus ATCC25293 (MIC for EtBr of 6 mg/L) that was 
induced to increased resistance to this dye [27] and was also 
inserted in this study as reference for fluorescence compari-
son. The fluorescence of the clinical isolates identified as 
HEMSA3, HEMSA4, HEMSA5 and HEMSA9 is greater 
than the one produced by the reference strain (S. aureus 
ATCC25923) and is almost as great as that needed for the 
fluorescence of the S. aureus ATCC25923EtBr strain that had 
been induced to high level resistance to EtBr and which 
over-expresses its NorA efflux pump [27] (Fig. 3). This fluo-
rescence can also be analyzed based on the Index for efflux 
activity of the isolates. This index allows classifying the 
level of efflux demonstrated by these strains, in order to rank 
the capacity to efflux EtBr of each bacterial strain (in com-
parison with the reference strain) [21]. 
 Efflux of EtBr was also analyzed among reference and 
clinical enterococci. It was visible the difference in fluores-
cence between the three E. faecalis strains and the two clini-
cal E. faecium (HSEFM-D and HSEFM-E). While at a con-
centration of 2 mg/L EtBr the Enterococcus faecalis strains 
show fluorescence, the E. faecium strains are starting to fluo-
resce [5, 21] (Fig. 3).  
THE EFFECT OF TEMPERATURE IN THE EFFLUX 
LEVEL OF THE CLINICAL ISOLATES 
 The EtBr-agar cartwheel method was also applied to test 
the effect of temperature on the efflux activity of the clinical 
isolates. Drug efflux is an energy-mediated transport and by 
using a low temperature that decreases the membrane energy 
we can decrease the efficiency of efflux transporters [6, 8]. 
As an example, two sets of TSA plates were streaked with 
the Acinetobacter strains and incubated at 37°C for a period 
of 18 hours. After this period, the fluorescence of the strains 
or the absence thereof was recorded (Fig. 4). The TSA plates 
were then re-incubated for an extra 24 hours; one set was 
returned to 37°C and the other transferred to 4°C to test if the 
efflux activity was the major contributor to the low levels of 
fluorescence previously registered. After this period the TSA 
plates were photographed again (Fig. 4). After a period of 
incubation at 4°C, strains that didn’t show fluorescence at 
37°C were highly fluorescent at the higher concentrations of 
EtBr tested in the agar plate. The same was obtained for all 
 
Fig. (3). The EtBr-agar cartwheel method applied to Gram-positive bacteria. 
Cultures were swabbed in TSA plates containing increasing concentrations of EtBr. Following overnight incubation at 37ºC for 16 hours, 
fluorescence was detected under UV light. The concentration shown above as an example for both strains is 2.0 mg/L of EtBr. Note: Data 
previously published in [21]. EFCATCC - Enterococcus faecalis reference strain; HSEFC – Enterococcus faecalis; HSEFM – Enterococcus 
faecium. 
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the other strains that didn’t show fluorescence or showed 
lower fluorescence than the reference strains (data not 
shown). 
 
Fig. (4). The effect of the temperature in the efflux activity of Acinetobacter strains screened by the EtBr-agar cartwheel method. 
The strains were streaked in the EtBr-TSA plates following the following scheme: 
 
ACI – Acinetobacter clinical isolate.  
The effect of the temperature on the efflux activity of the bacterial strains can be assessed by the EtBr-agar cartwheel method. As an exam-
ple, a set of Acinetobacter strains is illustrated in the figure. As visible, after a period of incubation at 4°C, strains that didn’t show fluores-
cence at 37°C are highly fluorescent at the higher concentrations of EtBr tested in the TSA plate. 







- + TZ + CPZ + PAN - + TZ + CPZ + PAN 
AG100 1 0.5 0.5 0.5 0.015 0.003 (5×) 0.003 (5×) 0.0075 
AG100TET 12 0.375 (32×) 3 (4×) 3 (4×) 0.06 0.015 (4×) 0.03 0.03 
HEMEC7 128 32 (4×) 16 (8×) 32 (4×) 0.25 0.125 0.125 0.125 
E. colia 
HEMEC10 64 32 16 (4×) 32 16 8 4 (4×) 2 (8×) 
TET NOR 
- + TZ + CPZ + PAN - + TZ + CPZ + PAN 
 
ATCC15038 
0.5 0.25 0.125 (4×) 0.5 0.025 0.0125 0.025 0.025 
 
Enterobacter aerogenesa 
HMEA11 2 1 0.25 (8×) 1 0.03 0.007 (4×) 0.003 (10×) 0.015 
TET CIP 
- + TZ + CPZ + PAN - + TZ + CPZ + PAN 
 
NCTC13349 
1 0.5 0.5 0.5 0.015 0.007 0.015 0.007 
 
Salmonellaa 
5408CIP 1 0.25 (4×) 0.5 0.5 32 8 (4×) 16 8 (4×) 
MER IMI  
- + TZ + CPZ + PAN - + TZ + CPZ + PAN 
ATCC 19606 4 2 2 0.25 (3×) 8 4 4 0.5 (4×) 
ACI7 128 64 (2×) 0.25 (9×) 16 (3×) ≥ 256 128 128 ≥ 256 
 
Acinetobacter 
ACI3 128 128 128 64 (2×) ≥ 256 128 128 ≥ 256 
TET - tetracycline; CIP - ciprofloxacin; NOR - norfloxacin; MER – meropenem; IMI – imipenem; TZ - thioridazine; CPZ - chlorpromazine; PAN - Phe-Arg-
napthylamide. aparcial data previously published in [21]. Solutions of TZ, CPZ and PAN (Sigma Aldrich, SA, Madrid, Spain) were prepared in deionized 
water. Aliquots of stock solutions of the phenothiazines CPZ and TZ were protected from light and stored at -20ºC. Working solutions were prepared on the 
day of the experiment. To assure that the efflux inhibitors do not compromise the bacterial viability, each compound was employed at a concentration of 1/2 of 
the MIC. Exceptions to this was PAN, known to affect the cellular viability even at 1/2 of the MIC [30] and in this case the compound was used at a maximum 
of 20 mg/L (value well below their pre-determined MIC). Values in bold-type correspond to a decrease of 4-fold or higher on the MIC values in comparison to 
the ones in the absence of inhibitor. Values in parenthesis indicate the MIC decrease relative to the one of the original culture. A reduction in the MIC of at 
least one-fourth of their original values in the presence of the efflux inhibitor was considered indicative of the presence of efflux activity. All assays were 
performed in triplicate. 
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CONFIRMATION OF THE RESULTS PROVIDED BY 
THE ETBR-AGAR CARTWHEEL METHOD  
 The results provided by the EtBr-agar cartwheel method 
were further explored by the additional determination of the 
MIC values for selected antibiotics, known to be efflux 
pump substrates (e.g. tetracycline, norfloxacin, imipenem, 
etc.), in the presence of compounds described as having an 
inhibitory effect on efflux activity. These compounds can 
include a variety of classes, such as efflux inhibitors, perme-
abilizers, chemosensitizers, etc. Ultimately, the intended use 
of these compounds is to confirm the activity of over-
expressed efflux system(s) in the MDR clinical strains iden-
tified by this method. This confirmation is important to rule 
out other factors that may affect fluorescence such as a de-
crease in the cellular permeability to EtBr [6, 8, 28, 29]. Iso-
lates that fluoresced at concentrations of EtBr significantly 
greater than their reference strains were evaluated for their 
susceptibility to a panel of antibiotics known to be substrates 
of efflux pump systems described for each bacterial species, 
in the presence and/or absence of compounds known to in-
hibit efflux activity. For comparative terms, representative 
strains showing fluorescence at low EtBr concentrations 
were also evaluated (Tables 1 and 2).  
 The efflux inhibitors used for Gram-negative and Gram-
positive bacteria can vary but some extensively studied com-
pounds are usually used such as: thioridazine (TZ), chlor-
promazine (CPZ), Phenylalanine-Arginine beta-Naphthy-
lamide (PAN) (in the case of Gram-negative bacteria) and 
TZ, CPZ and reserpine (RES) (in the case of Gram-positive 
bacteria) Table 3. To assure that the bacterial viability is not 
compromised by the presence of the efflux inhibitor itself, 
each compound was employed at a concentration of 1/2 of 
the MIC. Exceptions to this were PAN and RES; in the case 
of PAN, it is known to affect the cellular viability or mem-
brane permeability even at 1/2 of the MIC [13, 30]. In these 
specific cases (PAN and RES) the compounds were used at a 
maximum of 20 mg/L (value well below their pre-
determined MIC). A reduction in the MIC of at least 1/4 of 
their original values in the presence of the efflux inhibitor 
was considered indicative of the presence of efflux activity. 
All assays were performed in triplicate.  
 As can be seen by the data presented in Tables 1 and 2, 
there were significant reductions in the MIC values in the 
presence of the efflux inhibitors. For example, in the case of 
the E. coli strains there was a considerable reduction of the 
MIC of TET in the presence of the three compounds tested. 
This was observed in the TET-resistant strain and one the 
clinical isolates that showed lower levels of fluorescence 
(when compared with the control strain). Other reductions of 
the MIC were also obtained with CIP in the presence of the 
three inhibitors. The same was obtained for the Enterobacter 
aerogenes clinical isolates. Examples for these strains are 
shown in Table 1. While the clinical isolate HMEA11 
showed a reduction of the MIC to TET in the presence of 
CPZ, the MIC for NOR was reduced in the presence of CPZ 
as well as TZ. For the Salmonella strains an example is pre-
sented for TET and CIP, showing that TZ contributed to a 
Table 2. The Effect of Selected Efflux Inhibitors on the Resistance of Induced and MDR Gram-positive Bacteria 
  MIC for NOR (mg/L) 
Species Strains - + TZ + CPZ + RES 
ATCC25923 0.5 0.125 (4×) 0.125 (4×) 0.25 
ATCC25293EtBr 2 0.25 (8×) 0.25 (8×) 0.5 (4×) 
HEMSA 3  256 128 64 (4×) 128 
HEMSA 4  512 128 (4×) 128 (4×) 256 
HEMSA 5  64 16 (4×) 16 (4×) 32 
 
S. aureusa 
HEMSA 9  128 32 (4×) 64 64 
  MIC for TET (mg/L) 
 - + TZ + CPZ + RES 
EFC ATCC29212 4 4 4 4 
HSEFM-D  16 4 (4×) 4 (4×) 8 
 
Enterococcusa 
HSEFM-E 0.125 0.125 0.125 0.125 
TET - tetracycline; NOR - norfloxacin; CIP - ciprofloxacin; TZ - thioridazine; CPZ - chlorpromazine; RES - reserpine. aparcial data previously published in 
[21]. EFCATCC - Enterococcus faecalis reference strain; HSEFC – Enterococcus faecalis; HSEFM – Enterococcus faecium. Solutions of TZ and CPZ (Sigma 
Aldrich, SA, Madrid, Spain) were prepared in deionized water; RES (Sigma Aldrich, SA, Madrid, Spain) was prepared in dimethylsulfoxide. Aliquots of stock 
solutions of the phenothiazines CPZ and TZ were protected from light and stored at -20ºC. Working solutions were prepared on the day of the experiment. To 
assure that the efflux inhibitors do not compromise the bacterial viability, each compound was employed at a concentration of1/2 of the MIC. An exception to 
this is RES, known to affect the cellular viability even at 1/2 of the MIC [30] and in this case the compound was used at a maximum of 20 mg/L (value well 
below their pre-determined MIC). Values in bold-type correspond to a decrease of 4-fold or higher on the MIC values in comparison to the ones in the absence 
of inhibitor. Values in parenthesis indicate the MIC decrease relative to the one of the original culture. A reduction in the MIC of at least one-fourth of their 
original values in the presence of the efflux inhibitor was considered indicative of the presence of efflux activity. All assays were performed in triplicate.
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reduction  of  the MIC (4-fold reduction) of these antibiotics 
(Table 1). In the case of the Acinetobacter strains showed a 
reduction of the MIC of MER in the presence of CPZ and 
PAN. In the case of the Gram-positive strains, Staphylococ 
Table 3. Chemical Structures of EtBr, Antibiotics and Efflux Inhibitors Used in this Method 
Compounds  Designation Acronym Chemical Structure 
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Table 3. Contd….. 
Compounds  Designation Acronym Chemical Structure 







cus and Enterococcus there was a reduction of the MIC for 
NOR in the presence of TZ and CPZ for almost all of the 
strains tested; this reduction varied from 4- to 8-fold. Reser-
pine was able to reduce the MIC of NOR in the case of the 
EtBr-induced strain. In general, it was possible to confirm 
various degrees of efflux activity in the strains tested and 
that were previously identified and selected by the EtBr-agar 
cartwheel method. 
CONCLUDING REMARKS 
 Bacterial resistance to antibiotics has become a serious 
concern for the public health setting. Concomitantly, the role 
that efflux systems play in antibiotic resistance in MDR bac-
teria is an important subject that has been extensively dis-
cussed in recent years [1, 3, 22, 28]. Although high-level 
resistance may not occur as a result of MDR efflux pumps 
alone, the association of over-expression of specific genes 
among highly resistant clinical isolates cannot be ignored [3, 
24-26]. Therefore, we should bear in mind that the intrinsic 
resistance to antibiotics of some isolates may be largely due 
to efflux systems [19, 24, 31]. Synergic increases in resis-
tance seen with over-expression of efflux systems, as well as 
target site mutations can lead to highly resistant bacteria that 
are difficult to treat with the antibiotics that are currently 
available. The contribution of efflux to the resistance seen in 
some clinical strains needs to be considered as one of the 
parameter used in the design of future antibiotics or any 
other active compounds [32, 33]. In any event, alterations of 
the structure of a given antibiotic should be made to reduce 
the ability of that same antibiotic to be extruded from the 
bacterial cell, but without compromising its activity [8, 32, 
34]. Another approach could be based on potentiating the 
activity of antibiotics by these inhibitors/novel compounds 
[19, 20, 30, 32, 33]. The development of compounds that can 
act as inhibitors/blockers of efflux thereby reducing the im-
pact of these pumps on the efficacy of certain antibiotics, 
will be of clinical interest and could impact greatly on the 
clinical setting. However, the major challenge persists: to 
discover a compound that can be used as an efflux blocker in 
a non-specific manner, i.e., that can target a big range of 
efflux systems from different bacterial species. This could be 
considered a tangible goal as many of these systems show a 
high degree of structural homology between different bacte-
rial species [28, 29, 31, 34]. This approach can contribute to 
the design of more realistic synergic assays that can combine 
antibiotics and blockers to reduce the MIC for a given anti-
biotic to a clinical relevant level [20, 32, 33]. That way, bac-
teria initially resistant to antibiotics can become susceptible. 
If this approach proves to be successful in the future it can be 
used as an important alternative in the treatment of some of 
the most important MDR infections that we have to deal with 
nowadays [19, 20, 32, 35].  
 In summary, the EtBr-agar cartwheel method is easy to 
perform, less time-consuming and can be used to screen 
large numbers of bacterial strains, thereby facilitating the 
rapid identification of isolates displaying an MDR pheno-
type. It can be used in both Gram-negative and Gram-
positive clinical isolates to detect MDR mediated by efflux. 
It is also possible to establish a rapid comparison of efflux 
activity of laboratory derived isogenic mutants that were 
manipulated, in the case of strains that were adapted to a 
given antibiotic by sequential passage exposure; by deletion 
or interruption of a specific gene or cluster of genes; or by 
growing the strain in different conditions, for example: dif-
ferent temperature; different pH of the medium; others. 
Taken together, these factors may play a role in the efflux 
activity of the isolates, and all of these can be rapidly 
screened by the described Ethidium Bromide-agar Cartwheel 
method. 
LIST OF ABBREVIATIONS 
Bisbenzimide = Hoechst-33342  
CIP  = Ciprofloxacin  
CLSI  = Clinical and Laboratory Standards Insti-
tute  
CPZ  = Chlorpromazine  
EtBr = Ethidium bromide  
IMI = Imipenem 
MDR  = Multi-drug resistant  
MER = Meropenem 
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MIC  = Minimum inhibitory concentration  
NOR = Norfloxacin 
PAN  = Phenylalanine-Arginine beta-Naphthyla-
mide 
RES  = Reserpine  
TET  = Tetracycline  
TSA = Trypticase Soy Agar 
TZ  = Thioridazine  
U.V. = Ultraviolet 
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